Necrotizing Enterocolitis as a Rare Complication of Severe RSV Bronchiolitis in a Term Neonate: A Case Report With Narrative Review.

J Pediatr Health CareMar 26, 2026 (epub)

Paulo Sérgio Lucas da Silva, Emerson Yukio Kubo, Marcelo Cunio Machado Fonseca

✦ AI-curated · Sources linked

Case in brief

A previously healthy, full-term 24-day-old neonate was admitted with severe respiratory syncytial virus (RSV) bronchiolitis. The infant then developed abdominal distension, metabolic acidosis, and septic shock; imaging showed advanced necrotizing enterocolitis (NEC). The condition progressed despite intensive medical and surgical management, and the neonate died. The report describes NEC arising during severe RSV illness in a term infant without known risk factors, while noting that the relationship between RSV and NEC is uncertain.

What made this case unusual

Advanced NEC developed in a previously healthy, full-term neonate without known risk factors during severe RSV bronchiolitis, an uncommon association described in case reports and small series.

Diagnostic / clinical pearl

In severe RSV bronchiolitis, new abdominal distension or unexplained hemodynamic instability should prompt consideration of gastrointestinal complications, including NEC.

Source

Published in J Pediatr Health Care. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.